JAK2 and thrombocytosis disease: It also explains the mechanisms by which some ET patients only express JAK2 V617F in their platelets (49), and why some JAK2 V617F-positive PV patients only have erythrocytosis and thrombocytosis (50), in addition to those who have a complete panmyelopathy.